Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 5, 1997, Pages 489-495

  Ruggenenti, Piero ^b   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; RAMIPRIL;

CAPILLARY PRESSURE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW; ULTRAFILTRATION;

EID: 0030986521     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199709000-00014     Document Type: Review

References (32)

1. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2-15. A comprehensive and provocative overview of the pathogenetic mechanisms involved in the progression of chronic renal disease is provided, with particular focus on the central role of enhanced protein traffic through the glomerular barrier and on the renoprotective potential of those interventions that effectively decrease plasma protein Ultrafiltration by ameliorating the size-selective properties of the glomerular capillary wall.
2. Remuzzi G: Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 1995, 4:339-342.
3. Hosteller TH, Olson JI, Renke HG, Venkatachalam FA, Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981, 241:F85-F93.
4. Ruggenenti P, Remuzzi G: Antihypertensive agents and incipient diabetic nephropathy. In The Diabetes Annual, vol 9. Edited by Marshall SM, Home PD, Rizza RA. Amsterdam: Elsevier Science; 1995:295-317.
5. Ruggenenti P, Remuzzi G: The renoprotective action of angiotensin converting enzyme inhibitors in diabetes. Exp Nephrol 1996, 4(suppl1):53-60. This is an update and in-depth review of the mechanisms by which ACE inhibitors may ameliorate the glomerular barrier dysfunction, limit albuminuria and improve the outcome of nephropathy both in experimental and in human diabetes.
6. Remuzzi A, Mohamed EI: Impact of renin-angiotensin system blockade on structure and function of glomerular membrane components in animal models of kidney disease. Exp Nephrol 1996, 4(suppl1):27-33. An in-depth review of the effects of Ang II antagonism on the glomerular capillary is provided, with particular focus on the haemodynamic and structural changes that may result in preservation of the function of the capillary wall.
7. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G: Comparison of the effects of angiotensin-converting-enzyme inhibition and angiotensin Il receptor blockade on the evolution of spontaneous glomerular injury in male MFW/Ztm rats. Exp Nephrol 1996, 4:19-25. This paper provides the evidence that ACE inhibition and Ang II receptor antagonism have similar effects on glomerular capillary pressure, and on permeability and size-selective properties of the glomerular barrier.
8. Brunner FP, Thiel G, Hermle M, Bock A, Mihatsch M: Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989, 36:969-977.
9. Remuzzi A, Imberti O, Puntorieri S, Malanchini B, Macconi D, Magrini L, Bertani T, Remuzzi G: Dissociations between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in the rat. Am J Physiol 1994, 267:F1034-F1044.
10. Morelli E, Loon N, Meyer T, Peters W, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990, 39:76-82.
11. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Remuzzi G: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993, 6:36-43.
12. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991, 39:1267-1273.
13. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G: Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986, 30:488-496.
14. Rossing P, Hommel E, Smidt UM, Parving H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993, 42:715-719.
15. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK: Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995, 10:1353-1360.
16. Perna A, Remuzzi G: Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. Am J Kidney Dis 1996, 27:34-41. A positive correlation between urinary protein excretion rate and glomerular sclerosis demonstrated both in experimental models and in human disease, which provides evidence of the role of protein traffic in the pathogenesis of chronic renal injury.
17. Mallick NP, Short CD, Hunt LP: How far since Ellis? Nephron 1987, 46:113-124.
18. Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio JL: Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990, 8:525-531.
19. Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, Zoccali C, Scolari F, Maggiore Q, Tognoni G, Remuzzi G for the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): A randomized placebo controlled trial of the angiotensin-converting-enzyme inhibitor ramipril on the decline of the glomerular filtration rate and end stage renal failure in proteinuric, non-diabetic chronic renal disease. Lancet 1997, 349:1857-1863. This is the first clear-cut demonstration that, at similar levels of blood pressure control, ACE inhibitors slow the rate of GFR decline and limit progression to ESRF in chronic non-diabetic renal disease more effectively than do conventional antihypertensives because of their specific anti-proteinuric effect.
20. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN): A long-term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 1991, 3:193-202.
21. Ruggenenti P, Perna A, Lanzoni M, Vigano GL, Remuzzi G: In non diabetic chronic nephropathies urinary protein excretion rate segregates subgroups of patients with predictably different rates of GFR decline (ΔGFR) [Abstract]. J Am Soc Nephrol 1995, 6:401.
22. Wapstra FH, Navis G, de Jong PE, de Zeeuw D: Prognostic value of short term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol 1996, 4(suppl 1):47-52. Experimental and human evidence of a correlation between short-term reduction in proteinuria and long-term renoprotection is taken as indicating the pathogenetic role of proteinuria in the progression of chronic renal disease.
23. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992, 42:452-458.
24. Kamper AL, Straudgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992, 5:423-430.
25. Hannedouche T, Laudais P, Goldtarb B, El Esper N, Fournier A, Gadin M, Durand D, Chenard J, Mignon F, Sue JM, Griinfeld JP: Randomized controlled trial of enalapril and βblockers in non-diabetic chronic renal failure. Br Med J 1994, 309:833-837.
26. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ: Effect of angiotensin-converting-enzyme and calcium channel inhibition on progression of IgA nephropathy. In IgA Nephropathy: Pathogenesis and Treatment. Contributions to Nephrology. Edited by Clarkson AR. Woodroffe AJ. Basel: Karger; 1995, 111:184-193.
27. Ihle BU, Whitworth JA, Shahintar S, Cnaon A, Kincaid-Smith PS, Becker GJ: Angiotensin converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double blind trial. Am J Kidney Dis 1996, 27(suppl 4):489-495. Convincing evidence is given that ACE inhibitors more effectively decrease proteinuria and slow GFR decline than do conventional antihypertensives in hypertensive patients with non-diabetic renal disease.
28. Hansson L: Effects of angiotensin converting enzyme inhibition versus conventional antihypertensive therapy on the glomerular filtration rate. Cardiology 1995, 86(suppl 1):30-33.
29. Giatras I, Lau J, Levey AS: Effect of ACE inhibitors on the progression of non-diabetic renal disease: a meta-analysis [Abstract]. J Am Soc Nephrol 1996, 7:1318. This important meta-analysis of 10 published and unpublished trials shows that differences in blood pressure control between the treatment and control groups does not allow a specific renoprotective effect of ACE inhibitors in non-diabetic chronic renal disease to be concluded.
30. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P, ACE inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939-945. This is the largest clinical trial on ACE inhibitors performed so far in chronic renal disease, which provides important information on the natural history of different types of non-diabetic chronic nephropathies and on the renoprotective potential of ACE inhibitors in the proteinuric forms.
31. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995, 123:754-762.
32. Sawicki PT: Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995, 13:933-938.